Related Experiment Videos
Statin use is associated with reduced mortality in COPD.
V Søyseth1, P H Brekke, P Smith
1Department of Medicine, Akershus University Hospital, N-1478-Lørenskog, Norway. vidar.soyseth@medisin.uio.no
The European Respiratory Journal
|October 20, 2006
Summary
Statin treatment significantly reduces long-term mortality in patients with chronic obstructive pulmonary disease (COPD). Combining statins with inhaled corticosteroids further enhances survival benefits for COPD patients.
Area of Science:
- Cardiology
- Pulmonology
- Pharmacology
Background:
- Patients with chronic obstructive pulmonary disease (COPD) face a higher risk of ischaemic heart disease (IHD).
- Statins are established treatments for reducing mortality and morbidity in IHD.
- The potential survival benefits of statins in COPD patients warrant investigation.
Purpose of the Study:
- To investigate the association between statin treatment and long-term mortality in patients diagnosed with COPD exacerbation.
- To explore the combined effect of statins and inhaled corticosteroids (ICS) on survival in this patient group.
Main Methods:
- Retrospective cohort study design.
- Inclusion of 854 consecutive patients with COPD exacerbation.
- Median follow-up of 1.9 years with mortality data collection.
Main Results:
- Crude mortality rates were lower for statin users (110 per 1,000 person-years) compared to non-users (191 per 1,000 person-years).
- Adjusted analysis revealed a hazard ratio (HR) of 0.57 for statin users versus non-users (95% CI 0.38-0.87).
- Combined statin and ICS treatment showed the greatest survival benefit (HR 0.39, 95% CI 0.22-0.67) compared to no treatment.
Conclusions:
- Statin treatment is associated with improved survival following COPD exacerbation.
- Inhaled corticosteroids may augment the survival advantage conferred by statin therapy in COPD patients.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:26COPD: Management Using Bronchodilators and Corticosteroids
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:20COPD: Pathogenesis and Clinical Features
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
01:29Chronic Obstructive Pulmonary Disease-V: Management
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
01:27Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...